Paper25019388
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
Clark MP and 41 others. J Med Chem, 2014. Cited by 188 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. Papers, record 25019388. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25019388
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Aza Compounds | Major topic |
| Indoles | Major topic |
| RNA-Dependent RNA Polymerase | Major topic |
| Viral Proteins | Major topic |
| Administration, Oral | |
| Animals | |
| Biological Availability | |
| Dogs | |
| Drug Resistance, Viral | |
| Influenza A virus | |
| Madin Darby Canine Kidney Cells | |
| Male | |
| Mice, Inbred BALB C | |
| Models, Molecular | |
| Molecular Structure | |
| Orthomyxoviridae Infections | |
| Rats | |
| Species Specificity | |
| Stereoisomerism | |
| Structure-Activity Relationship | |
| Virus Replication |
Source PubMed
Cited by99
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 188 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,844,389 | Towards broader-spectrum direct-acting antivirals against RNA viruses. | Nat Rev Microbiol | 2026 | https://conductscience.org/library/papers/42844389 | PubMed |
| 42,568,525 | From neuraminidase inhibitors to novel mechanisms: expanding therapeutic strategies against influenza. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42568525 | PubMed |
| 42,513,991 | A Structural View of Influenza Virus Ribonucleoprotein Complex and Its Functions. | Microorganisms | 2026 | https://conductscience.org/library/papers/42513991 | PubMed |
| 42,434,556 | A scoping review of influenza RdRp-targeting inhibitors: mechanisms, clinical translation, and emerging challenges. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42434556 | PubMed |
| 42,427,235 | Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit. | Emerg Microbes Infect | 2026 | https://conductscience.org/library/papers/42427235 | PubMed |
| 41,685,158 | Anti-influenza drugs targeting trimeric RNA polymerase complex: From development to clinics. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/41685158 | PubMed |
| 41,187,142 | Antibacterial and antiviral potential of harmalacidine hydrochloride, a β-carboline alkaloid, against respiratory tract pathogens: Staphylococcus aureus and H1N1 influenza virus. | PLoS One | 2025 | https://conductscience.org/library/papers/41187142 | PubMed |
| 41,105,303 | Antiviral strategies against H5N1: current options and emerging therapeutics. | Infection | 2026 | https://conductscience.org/library/papers/41105303 | PubMed |
| 40,864,651 | CRISPR with Transcriptional Readout reveals influenza transcription is modulated by NELF and can precipitate an interferon response. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/40864651 | PubMed |
| 40,839,799 | Making Sense of Heteroatom Effects in π-π Interactions. | J Am Chem Soc | 2025 | https://conductscience.org/library/papers/40839799 | PubMed |
| 40,484,321 | High-throughput screening for identification of influenza a inhibitors using a cell-based immunofluorescence assay. | Antiviral Res | 2025 | https://conductscience.org/library/papers/40484321 | PubMed |
| 40,439,048 | Revisiting the Hunter-Sanders Model for π-π Interactions. | J Am Chem Soc | 2025 | https://conductscience.org/library/papers/40439048 | PubMed |
| 40,146,533 | Stacking Interactions of Druglike Heterocycles with Nucleobases. | J Chem Inf Model | 2025 | https://conductscience.org/library/papers/40146533 | PubMed |
| 39,992,105 | A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug-drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/39992105 | PubMed |
| 39,775,042 | Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. | Nat Med | 2025 | https://conductscience.org/library/papers/39775042 | PubMed |
| 39,163,780 | Indole-core inhibitors of influenza a neuraminidase: iterative medicinal chemistry and molecular modeling. | Eur J Med Chem | 2024 | https://conductscience.org/library/papers/39163780 | PubMed |
| 38,681,787 | Latest developments in early diagnosis and specific treatment of severe influenza infection. | J Intensive Med | 2024 | https://conductscience.org/library/papers/38681787 | PubMed |
| 38,551,343 | Retracted and republished from: "The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs". | mBio | 2024 | https://conductscience.org/library/papers/38551343 | PubMed |
| 38,283,223 | Recent advances of phenotypic screening strategies in the application of anti-influenza virus drug discovery. | RSC Med Chem | 2024 | https://conductscience.org/library/papers/38283223 | PubMed |
| 38,005,857 | Covalent Inhibitors from Saudi Medicinal Plants Target RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2. | Viruses | 2023 | https://conductscience.org/library/papers/38005857 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25019388
GET https://conductscience.org/api/papers/v1/25019388/authors?page=2